These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 18721759)
1. Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells. Foley JE; Mariotti J; Ryan K; Eckhaus M; Fowler DH Biol Blood Marrow Transplant; 2008 Sep; 14(9):959-972. PubMed ID: 18721759 [TBL] [Abstract][Full Text] [Related]
2. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. Murphy WJ; Welniak LA; Taub DD; Wiltrout RH; Taylor PA; Vallera DA; Kopf M; Young H; Longo DL; Blazar BR J Clin Invest; 1998 Nov; 102(9):1742-8. PubMed ID: 9802888 [TBL] [Abstract][Full Text] [Related]
3. Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism. Foley JE; Jung U; Miera A; Borenstein T; Mariotti J; Eckhaus M; Bierer BE; Fowler DH J Immunol; 2005 Nov; 175(9):5732-43. PubMed ID: 16237064 [TBL] [Abstract][Full Text] [Related]
4. Donor bone marrow type II (non-Valpha14Jalpha18 CD1d-restricted) NKT cells suppress graft-versus-host disease by producing IFN-gamma and IL-4. Kim JH; Choi EY; Chung DH J Immunol; 2007 Nov; 179(10):6579-87. PubMed ID: 17982047 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of graft-versus-host disease by interleukin-2 treatment is associated with altered cytokine production by expanded graft-versus-host-reactive CD4+ helper cells. Wang MG; Szebeni J; Pearson DA; Szot GL; Sykes M Transplantation; 1995 Sep; 60(5):481-90. PubMed ID: 7676498 [TBL] [Abstract][Full Text] [Related]
6. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy. Jung U; Foley JE; Erdmann AA; Toda Y; Borenstein T; Mariotti J; Fowler DH Biol Blood Marrow Transplant; 2006 Sep; 12(9):905-18. PubMed ID: 16920556 [TBL] [Abstract][Full Text] [Related]
7. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. Yang YG; Dey BR; Sergio JJ; Pearson DA; Sykes M J Clin Invest; 1998 Dec; 102(12):2126-35. PubMed ID: 9854048 [TBL] [Abstract][Full Text] [Related]
8. IFN-γ receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation. Sun K; Hsiao HH; Li M; Ames E; Bouchlaka M; Welniak LA; Hagino T; Jagdeo J; Pai CC; Chen M; Blazar BR; Abedi M; Murphy WJ J Immunol; 2012 Aug; 189(4):2033-42. PubMed ID: 22778394 [TBL] [Abstract][Full Text] [Related]
9. Combined Th2 cytokine deficiency in donor T cells aggravates experimental acute graft-vs-host disease. Tawara I; Maeda Y; Sun Y; Lowler KP; Liu C; Toubai T; McKenzie AN; Reddy P Exp Hematol; 2008 Aug; 36(8):988-96. PubMed ID: 18410989 [TBL] [Abstract][Full Text] [Related]
10. Viral IL-10-induced immunosuppression requires Th2 cytokines and impairs APC function within the allograft. Qin L; Ding Y; Tahara H; Bromberg JS J Immunol; 2001 Feb; 166(4):2385-93. PubMed ID: 11160297 [TBL] [Abstract][Full Text] [Related]
11. CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects. Jung U; Foley JE; Erdmann AA; Eckhaus MA; Fowler DH Blood; 2003 Nov; 102(9):3439-46. PubMed ID: 12855580 [TBL] [Abstract][Full Text] [Related]
12. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation. Min CK; Maeda Y; Lowler K; Liu C; Clouthier S; Lofthus D; Weisiger E; Ferrara JL; Reddy P Blood; 2004 Nov; 104(10):3393-9. PubMed ID: 15280194 [TBL] [Abstract][Full Text] [Related]
13. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Fowler DH; Gress RE Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730 [TBL] [Abstract][Full Text] [Related]